Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

IELSG 42

Title

IELSG 42 - An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autologous stem cell transplant, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse (MARIETTA regimen). 

Objectives

This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT.

Primary Endpoint:

  • 1-year progression-free survival (PFS)

Secondary Endpoints:

  • Complete remission rate before autologous stem cell transplantation
  • Response duration
  • Overall survival
  • Safety

Trial Status

Open to recruitment

Population

This is an international trial looking to recruit 76 patients (to include 20 UK patients). 

Stand up to cancer logo
IELSG 42 is supported by Stand Up To Cancer

Trial Team:

Senior Trial Manager:

Kelly Cozens (023 8120 8834)

Trial Manager:

Marina Lee (023 8120 3747)

Contact information

Email: ielsg42@soton.ac.uk

Fax: 0844 7740 621

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×